Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $14.56
Previous CloseN/A
Volume45.37K
Average Volume (3M)393.39K
Market Cap
$242.69M
Enterprise Value$183.50M
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Aug 06, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume136,495
30 Day Avg. Volume393,390
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue103.38
Enterprise Value/Gross Profit-16.65
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$33.83Price Target Upside380.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$549.50K
Bulls Say, Bears Say
Bulls Say
In‑vivo CAR‑T Licensing AllianceThe WestGene licensing deal gives Cartesian an in‑vivo delivery route that can eliminate ex‑vivo manufacture for some programs. That materially lowers manufacturing complexity and unit costs and accelerates clinical translation, strengthening the company's platform and competitive moat over the medium term.
Material Non‑Dilutive Credit FacilityThe up to $150M facility (initial $50M funded) materially extends cash runway into 2028 and supports late‑stage development activities. Non‑dilutive capital backed by assets improves near‑term funding stability and allows execution of planned Phase 3/2 catalysts without immediate equity issuance.
Governance ContinuityStrong shareholder support for the board and the ratification of a major auditor indicate stable governance and oversight. Continuity in leadership and external financial controls reduces execution and reporting risk, aiding long‑term strategic consistency during clinical execution.
Bears Say
Heavy Cash BurnSustained large negative operating and free cash flows imply the business cannot self‑fund development. Persistent burn increases dependency on external financing and raises dilution or covenant risk if clinical or milestone triggers for credit tranches are delayed or fail to materialize.
Negative EquityMaterial negative equity signals accumulated losses and weak book value, reducing balance sheet flexibility. Even with modest nominal debt, negative equity heightens recapitalization and dilution risk and can complicate future financing or partnership negotiations if clinical progress stalls.
Deteriorating Revenue & MarginsSharp revenue decline and deeply negative margins reflect deteriorating operational performance and limited commercial revenue streams. Negative gross profit undermines scalability and indicates that current operations cannot absorb R&D and G&A, increasing reliance on successful clinical outcomes to restore earnings quality.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $14.56 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $242.69M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 29,381,514 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (380.59% Upside)
$33.83 (380.59% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.07%
12-Months-Change
Fundamentals
Return on Equity
194.13%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Stock 12 Month Forecast
Average Price Target
$33.83
▲(380.59% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.17% Insiders
7.32% Mutual Funds
3.32% Other Institutional Investors
40.30% Public Companies and
Individual Investors